AC Immune SA

What they do

AC Immune discovers and develops therapies and diagnostics targeting misfolded proteins such as amyloid beta and tau, which are implicated in Alzheimer's disease and other neurodegenerative conditions. The company operates a pipeline of vaccine and small-molecule candidates, including its Morphomer and SupraAntigen platforms. It is headquartered in Lausanne, Switzerland, and has one subsidiary. The company reported 101,742,231 common shares outstanding as of the period covered by its annual report.

Revenue drivers

• Grant and collaboration revenue — The company has historically generated revenue from research grants and collaborative agreements with pharmaceutical partners; no specific figures were provided in the excerpt.
• Licensing and milestone payments — Potential future revenue may come from license fees and milestone payments tied to its pipeline programs; no active deals are detailed in the provided excerpt.
• Diagnostics — AC Immune also develops diagnostic tools related to its therapeutic targets, though no revenue contribution is specified in the excerpt.

Recent performance

The provided excerpt does not include financial results for the fiscal year ended December 31, 2025, beyond the number of outstanding shares. No revenue, net income, or cash position figures are available in the excerpt. Therefore, recent performance cannot be summarized from the source material.

Strategy

AC Immune's stated strategy focuses on advancing its pipeline of neurodegenerative disease candidates, leveraging its Morphomer and SupraAntigen technology platforms. The company aims to progress clinical programs both independently and through collaborations. No specific strategic priorities or investments are detailed in the excerpt.

Risks

• Clinical development risk — As a clinical-stage company, AC Immune faces substantial uncertainty regarding the success of its product candidates in clinical trials.
• Regulatory approval risk — Obtaining regulatory approvals for its therapies is uncertain and may be delayed or denied.
• Financing risk — The company may need additional capital to fund its operations and research, which may not be available on acceptable terms.
• Competition risk — AC Immune operates in a highly competitive field with many other companies developing treatments for neurodegenerative diseases.

Outlook

The provided excerpt does not contain management's outlook or forward-looking guidance for future periods. No outlook statement can be provided based on the source material.